ABVX vs PVLA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABVX and PVLA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABVX and PVLA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Abivax SA is a French clinical-stage biopharmaceutical company listed on Nasdaq via a sponsored ADR (ABVX). Its lead and effectively sole value driver is obefazimod (formerly ABX464), a first-in-class oral miR-124 enhancer being developed for inflammatory bowel disease. In 2025 and 2026 the pivotal Phase 3 ABTECT program in moderate-to-severe ulcerative colitis reported positive results across both induction trials and the maintenance trial, with the 50 mg dose showing clinical remission around 51% at Week 44 versus roughly 10% for placebo. Management has guided toward a U.S. FDA new drug application filing in late 2026, with a Phase 2b Crohn's disease readout expected around mid-2027.

Full ABVX guide

Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company, founded in 2015 and based in Wayne, Pennsylvania, that develops therapies for serious, rare skin diseases with no FDA-approved treatments. Its platform is QTORIN, a proprietary topical (anhydrous gel) formulation of rapamycin. The lead program, QTORIN 3.9% rapamycin, targets microcystic lymphatic malformations (an estimated 30,000-plus U.S. patients) and carries FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations. In early 2026 the company reported positive topline Phase 3 SELVA results, began a rolling NDA submission mid-2026 with completion targeted for the second half of 2026, and pointed to potential U.S. approval in the first half of 2027. Additional programs include cutaneous venous malformations (TOIVA), angiokeratomas (LOTU), pachyonychia congenita, and QTORIN pitavastatin for DSAP.

Full PVLA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• ABVX drivers: Positive Phase 3 obefazimod data; Path to an FDA filing.
• PVLA drivers: QTORIN rapamycin approval path in microcystic LMs; Pipeline expansion across rare dermatology.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a single-asset biotech, essentially all of Abivax's value depends on obefazimod, so a regulatory rejection, a delay, or a negative safety finding could sharply reduce the shares. For PVLA, as a pre-revenue clinical-stage biotech, Palvella has no product sales and reports growing net losses (about $15.8 million in Q1 2026), so results depend on future regulatory and commercial outcomes.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABVX if you believe its drivers more; PVLA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABVX and PVLA guides.

ABVX. Abivax has effectively no product revenue and posts large net losses, which is normal for a clinical-stage biotech funding pivotal trials rather than a warning sign on its own. Traditional earnings multiples do not apply; the market instead values the probability-weighted potential of obefazimod reaching and selling in the market. The mid-2026 capital raise materially extended the runway and reduced near-term financing risk.

PVLA. Palvella generates essentially no product revenue and is valued on the expected commercial potential of QTORIN rapamycin, not current earnings. With roughly $262 million in cash against a market cap near $1.7 billion, the stock reflects optimism about a first-in-disease franchise. Standard earnings multiples do not apply to a pre-revenue biotech, so the balance sheet, trial data, and regulatory timeline matter more than valuation ratios.

Headline figures (approximate, July 2026): ABVX shows market cap ~$7-8B, product revenue (ttm) ~negligible (pre-commercial), net loss (fy2025) ~EUR 336M, r&d expense (fy2025) ~EUR 178M; PVLA shows product revenue (ttm) ~$0 (pre-commercial), net loss (q1 2026) ~$15.8M, r&d expense (q1 2026) ~$9.3M, cash + short-term investments ~$262M.

ABVX and PVLA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABVX and PVLA exposure against your real portfolio. It is not an investment adviser.